|

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

RECRUITINGN/ASponsored by Ankara University
Actively Recruiting
PhaseN/A
SponsorAnkara University
Started2025-11-01
Est. completion2026-08-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07436455

Summary

In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
* Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
* Negative or equivocal I-131 whole-body scan findings
* Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status)
* Giving written informed consent

Exclusion Criteria:

* Age under 18 years
* Pregnancy or breastfeeding
* Failure to provide written informed consent

Conditions3

CancerDifferentiated Thyroid CancerThyroid Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.